Conditions: Healthy Volunteers
Allocation: RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 80
Healthy volunteers: yes

Brief summary:
The main purposes of this study are to evaluate the safety and how well the body handles single and multiple doses of increasing strength of study drug, LY3127760. This study includes three parts. Part 3 may be initiated at sponsor's discretion, based on data from Part 2. Participants will only enroll in 1 of the 3 study parts. This study will last approximately 7 to 13 weeks, depending on part. Screening must be completed within 28 days prior to enrollment.

Detailed description:

Arms:
arm 1: Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods. arm 2: Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance. arm 3: Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days. arm 4: Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance. arm 5: Multiple oral doses of 400 mg celecoxib administered QD for 28 days.

Interventions: intervention 1: LY3127760 intervention 2: Celecoxib intervention 3: Placebo
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally intervention 3: Administered orally

Protocol document: